Insilico Medicine vs Insitro

By valuation, Insitro is the larger company at $2.2B versus $1.2B — a 1.8x difference. Size can also be measured by team: Insilico Medicine employs 350 people while Insitro has 300 employees.

Insitro has raised more in total funding at $743M, compared to Insilico Medicine's $500M — a gap of $243M. Combined, the two companies have completed 6 known funding rounds.

Insitro leads with an Awaira Score of 73/100, while Insilico Medicine sits at 67/100. That 6-point gap reflects real differences in funding, scale, and traction — it's not a vanity metric.

Insilico Medicine was founded by Alex Zhavoronkov in 2014. Insitro was founded by Daphne Koller in 2018. Visit each company's profile on Awaira for a full founder biography.

Insilico Medicine: Insilico Medicine is an AI-driven drug discovery and development company founded in 2014 and headquartered in the USA. The company applies artificial intelligence, machine learning, and generative models to accelerate the identification and optimization of drug candidates across multiple therapeutic areas. Its core platform integrates physics-based modeling with deep learning to predict molecular properties, identify disease targets, and design novel compounds with improved efficacy and reduced toxicity. The company operates across several segments: AI-powered target identification, lead optimization, and clinical trial optimization. Notable applications include oncology, aging-related diseases, and fibrosis. Insilico Medicine has demonstrated its technology through partnerships with pharmaceutical companies and biotech firms seeking to reduce drug development timelines and costs. The platform has been applied to various disease targets, with some candidates advancing through development stages. With $403 million in total funding and a valuation of $1.2 billion, Insilico Medicine represents a significant player in the AI healthcare sector. The company went public, reflecting investor confidence in its technology platform and business model. Its competitive position centers on the integration of generative AI models with molecular biology expertise. The company competes alongside other AI drug discovery platforms while differentiating through its aging research focus and established pharma partnerships. Insilico Medicine uniquely combines generative AI with longevity research, targeting age-related diseases while maintaining traditional pharma collaboration channels. Insitro: Insitro is an AI-driven drug discovery company founded in 2018 that applies machine learning to accelerate pharmaceutical development. The company combines computational biology, artificial intelligence, and wet-lab experimentation to identify and validate drug targets more efficiently than traditional methods. Insitro's platform uses proprietary algorithms to analyze complex biological data, predict drug efficacy and safety profiles, and optimize candidate selection across therapeutic areas including metabolic disease, oncology, and immunology. The company has raised $743 million across multiple funding rounds, achieving a valuation of $2.2 billion as of its Series C stage. This positions Insitro among well-capitalized AI healthcare startups addressing the structural inefficiencies in drug discovery. The company partners with pharmaceutical institutions to apply its technology to their pipelines, utilizing both internal discovery programs and collaborations. Insitro's competitive approach differs from pure software platforms by integrating experimental validation, reducing the translation gap between computational predictions and real-world drug performance. The company operates in a crowded but expanding market of AI drug discovery platforms competing against both established pharma AI initiatives and other venture-backed startups. Its growth trajectory reflects investor confidence in AI-enabled drug discovery models, though clinical validation remains ongoing for internally developed candidates. Insitro uniquely combines machine learning with integrated wet-lab capabilities rather than operating as pure software, bridging computational predictions to experimental validation.

Insilico Medicine got there first, launching in 2014 — that's 4 years of extra runway. Insitro didn't arrive until 2018. In AI, that kind of head start means more training data, deeper customer relationships, and a bigger talent moat.

Insilico Medicine has about 350 employees; Insitro has about 300. A bigger team usually means more revenue or heavier VC backing, but in AI, small teams can build at massive scale.

Yes — they're direct rivals. Both Insilico Medicine and Insitro compete in AI Healthcare, targeting many of the same buyers. If you're evaluating one, you should be looking at the other.